SCHEMBL5159835

SCHEMBL5159835

COc1cc2ccccc2c2c1cc(CO)n2CC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.46
CNR1 P21554 7/20 0.40
NUAK1 O60285 1/20 0.40
JAK2 O60674 1/20 0.40
NTRK1 P04629 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
FLT3 P36888 1/20 0.40
JAK3 P52333 1/20 0.40
NUAK2 Q9H093 1/20 0.40
BMP2K Q9NSY1 1/20 0.40
HTT P42858 1/20 0.40
MAPK8 P45983 1/20 0.38
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR2 P34972 4/20 0.37
KDM2B Q8NHM5 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162888 0.85 PLA2G2A (0.48) PLA2G2ACNR1NUAK1JAK2NTRK1
SCHEMBL5159760 0.79 KMT2A (0.49) PLA2G2ACNR1HTTMAPK8L3MBTL1
SCHEMBL5158958 0.72 PLA2G2A (0.66) PLA2G2ANUAK1JAK2NTRK1JAK1
SCHEMBL14608169 0.70 PLA2G10 (0.41) PLA2G2AHTTPLA2G1B
SCHEMBL26670917 0.69 GRIN2B (0.38) KDM2B
SCHEMBL26660662 0.64 KDM2B (0.44) CNR1L3MBTL1CNR2KDM2BTDP1
SCHEMBL31501905 0.64 GRM2 (0.38) CNR1MAPK8CNR2KDM2B
SCHEMBL26660745 0.64 GRM2 (0.38) CNR1MAPK8CNR2KDM2B
SCHEMBL6339378 0.64 PLA2G2A (0.46) PLA2G2A
SCHEMBL26670766 0.64 MCL1 (0.33) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A PLA2G2A 16/4885CNR1 3603/4885NUAK1 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.